Skip to main content
. 2022 Apr 11;8(2):00724-2021. doi: 10.1183/23120541.00724-2021

TABLE 1.

Individual and encounter-level characteristics at baseline and censoring time

Baseline Censored #
Gender
 Male 9137 (52.5)
 Female 8266 (47.5)
Mutation category
 Class 1 4062 (23.3)
 Class 2 15043 (86.4)
 Class 3 1007 (5.8)
 Class 4 1068 (6.1)
 Class 5 1120 (6.4)
 Unknown 668 (3.8)
 F508del only 7827 (45.0)
Least severe mutation
 Class 1/2 13614 (78.2)
 Class 3 950 (5.5)
 Class 4/5 2171 (12.5)
 Unknown 668 (3.8)
Age
 12 to <18 years 6554 (37.7) 3694 (21.2)
 ≥18 years 10849 (62.3) 13709 (78.8)
FEV1pp
 Normal 3923 (22.5) 4313 (24.8)
 Mild 4840 (27.8) 5125 (29.4)
 Moderate 4959 (28.5) 5597 (32.2)
 Severe 1210 (6.9) 2256 (13.0)
 Unknown 2471 (14.2) 112 (0.6)
BMI
 Underweight 1135 (6.5) 1282 (7.4)
 Normal 11517 (66.2) 10940 (62.9)
 Overweight 2345 (13.5) 2852 (16.4)
 Obese 839 (4.8) 1045 (6.0)
 Unknown 1567 (9.0) 1284 (7.4)
Chronic macrolides 7620 (43.8) 8192 (47.1)
NTM positive 4077 (23.4)
 Culture positive for MAB only 1203 (6.9)
 Culture positive for MAC only 2066 (11.9)
 Culture positive for other species only 741 (4.3)
 Culture positive for multiple species 67 (0.4)
Any modulator therapy 7384 (42.4)
 Ever received ivacaftor monotherapy 1893 (10.9)
 Ever received combination therapy 5869 (33.7)
 Neither 10019 (57.6)

Data are presented as n (%). FEV1pp: percentage predicted forced expiratory volume in 1 s; BMI: body mass index; NTM: nontuberculous mycobacteria; MAB: Mycobacterium abscessus; MAC: Mycobacterium avium complex. #: censor: NTM-positive culture or patient's last time point in dataset; : ≥1.